HTG Molecular Diagnostics, Inc. provided revenue guidance for full year 2022. For the period, total revenue is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of total revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | +66.67% | 0.00% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-12.36% | 19.25B | |
-40.05% | 2.96B | |
+23.79% | 1.96B | |
+1.29% | 1.69B | |
+28.87% | 1.27B | |
-14.61% | 982M | |
-20.31% | 913M | |
+3.53% | 801M | |
-24.78% | 630M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022